Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial.

@article{Romieu2007PegfilgrastimSD,
  title={Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial.},
  author={Gilles H Romieu and Michael Clemens and Rolf Mahlberg and Pierre Fargeot and Manuel Constenla and Martin Sch{\"u}tte and Valerie Easton and Tom{\'a}s Sk{\'a}cel and Pamela L. Bacon and W. E. Brugger},
  journal={Critical reviews in oncology/hematology},
  year={2007},
  volume={64 1},
  pages={64-72}
}
This randomized phase 2 study explored the feasibility of delivering four to six cycles of the dose-intensified regimen FEC-100 (5-fluorouracil, epirubicin, and cyclophosphamide) to elderly patients with stage II-III breast cancer, using pegfilgrastim for neutrophil support. Sixty patients aged 65-77 years received single 6mg doses of pegfilgrastim on day 2 of FEC-100, either as primary prophylaxis (all cycles: PP), or as secondary prophylaxis (all cycles following a neutropenic event: SP… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Similar Papers

Loading similar papers…